Evidence map›Paper›PMID 32094403›Full record

ArticleOncogene2020

Correction: Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases.

Chi Zhang, Simon R Stockwell, May Elbanna, Robin Ketteler, Jamie Freeman, Bissan Al-Lazikani, Suzanne Eccles, Alexis De Haven Brandon, Florence Raynaud, Angela Hayes and 3 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Chi ZhangUCL Cancer Institute, University College London, London, WC1E 6DD, UK.
Simon R StockwellUCL Cancer Institute, University College London, London, WC1E 6DD, UK.ORCID http://orcid.org/0000-0002-3345-8945
May ElbannaUCL Cancer Institute, University College London, London, WC1E 6DD, UK.
Robin KettelerMRC Laboratory for Molecular Cell Biology, University College London, London, WC1E 6BT, UK.
Jamie FreemanMRC Laboratory for Molecular Cell Biology, University College London, London, WC1E 6BT, UK.
Bissan Al-LazikaniCancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, SM2 5NG, UK.
Suzanne EcclesCancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, SM2 5NG, UK.
Alexis De Haven BrandonCancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, SM2 5NG, UK.
Florence RaynaudCancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, SM2 5NG, UK.
Angela HayesCancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, SM2 5NG, UK.
Paul A ClarkeCancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, SM2 5NG, UK.ORCID http://orcid.org/0000-0001-9342-1290
Paul WorkmanCancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, SM2 5NG, UK. paul.workman@icr.ac.uk.ORCID http://orcid.org/0000-0003-1659-3034
Sibylle MittnachtUCL Cancer Institute, University College London, London, WC1E 6DD, UK. s.mittnacht@cancer.ucl.ac.uk.

Funding

Cancer Research UK 22897Cancer Research UK 23187Medical Research Council MC_EX_G0800785
6 · The paper itself

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Identifiers

PMID32094403
PMCPMC7160058

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.